ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has received approval, including a positive determination for the pricing and reimbursement, for ILUVIEN for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye from the Italian Medicines Agency, AIFA.
Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
